{"entity":{"id":"paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022","kind":"paper","name":"GOG 281/LOGS: trametinib versus standard of care in recurrent low-grade serous ovarian cancer","aka":[],"tldr":"The MEK inhibitor trametinib more than doubled the time to progression compared with chemotherapy or hormone therapy in recurrent low-grade serous ovarian cancer, the first positive randomised trial in this slow-growing, chemotherapy-resistant disease.","summary":"Phase 2/3 trial of 260 patients with recurrent low-grade serous carcinoma of the ovary or peritoneum randomised to trametinib or investigator's choice of letrozole, tamoxifen, weekly paclitaxel, pegylated liposomal doxorubicin or topotecan.\n\nMedian progression-free survival was 13.0 versus 7.2 months (hazard ratio 0.48) and response 26 versus 6 percent; skin rash, anaemia and hypertension were common with trametinib.","asOf":"2026-09-17","links":[{"label":"Lancet 2022","url":"https://doi.org/10.1016/S0140-6736(21)02175-9"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/35123694/"}],"tags":[],"related":[],"cancers":["low-grade-serous-ovarian-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["trametinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet"],"dependsOn":[],"notes":[],"journal":"The Lancet","year":2022,"doi":"10.1016/S0140-6736(21)02175-9","pmid":"35123694","authors":"Gershenson DM, Miller A, Brady WE, et al.","paperType":"rct","findings":["Median progression-free survival 13.0 vs 7.2 months; hazard ratio 0.48.","Objective response 26 percent vs 6 percent."],"whatItMeans":"MEK inhibition is a standard option for recurrent low-grade serous ovarian cancer, and the trial validated the MAPK pathway as the disease's therapeutic target, now extended by avutometinib-defactinib.","caveats":["Open-label; overall survival not significantly different with crossover.","Toxicity led to dose reductions in many patients."],"changedPractice":true,"participants":260},"route":"/key-papers/paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022/","neighbours":{"cancer":[{"id":"low-grade-serous-ovarian-cancer","kind":"cancer","name":"Low-grade serous ovarian cancer","route":"/cancers/low-grade-serous-ovarian-cancer/"}],"drug":[{"id":"trametinib","kind":"drug","name":"Trametinib","route":"/drugs/trametinib/"}],"journal":[{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/"}]}}